# Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

> **NCT05769153** · PHASE1,PHASE2 · RECRUITING · sponsor: **Alcon Research** · enrollment: 140 (estimated)

## Conditions studied

- Neovascular Age-related Macular Degeneration (nAMD)

## Interventions

- **DRUG:** AR-14034 SR implant lower dose
- **DRUG:** AR-14034 SR implant higher dose
- **DRUG:** AR-14034 SR implant
- **DRUG:** Aflibercept Injection
- **DRUG:** Sham procedure

## Key facts

- **NCT ID:** NCT05769153
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-06
- **Primary completion:** 2027-10
- **Final completion:** 2027-10
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05769153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05769153, "Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05769153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*